In preclinical murine models of osteosarcoma, when used alone or in combination with other therapies, antibodies against CTLA‐4 or PD‐1 have shown benefit by upregulating the antitumor activity of cytotoxic T cells.11, 12, 13. This evidence concerns the gene CTLA4 and osteosarcoma.